Status:
COMPLETED
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Anxiety
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to compare pregabalin to Venlafaxine XR and placebo in the treatment of generalized anxiety disorder.
Eligibility Criteria
Inclusion
- Male and female outpatients with diagnosis of generalized anxiety disorder.
Exclusion
- Any serious or uncontrolled medical condition.
- Current diagnosis of depression, dysthymia, obsessive-compulsive disorder.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
390 Patients enrolled
Trial Details
Trial ID
NCT00151450
Start Date
March 1 2005
End Date
November 1 2006
Last Update
January 22 2021
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
De Pinte, Belgium
2
Pfizer Investigational Site
Ghent, Belgium
3
Pfizer Investigational Site
Waregem, Belgium
4
Pfizer Investigational Site
Kelowna, British Columbia, Canada